| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C0001795> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C0007667> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C0019994> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C0028296> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C0028829> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C0041703> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C2936643> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C2985546> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/35037816_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'Humanigen Inc, Burlingame, CA, United States.\', \'EVERSANA, Burlington, ON, Canada.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Amarapala_Miyuru> <https://research.tib.eu/covid-19/entity/Chappell_Dale> <https://research.tib.eu/covid-19/entity/Hughes_Avery> <https://research.tib.eu/covid-19/entity/Jordan_Edward> <https://research.tib.eu/covid-19/entity/Kilcoyne_Adrian> <https://research.tib.eu/covid-19/entity/Pepper_Alicia_N> <https://research.tib.eu/covid-19/entity/Thomas_Kimberly> <https://research.tib.eu/covid-19/entity/Thompson_Melissa> <https://research.tib.eu/covid-19/entity/Zhou_Allen>
?:doi	10.1080/13696998.2022.2030148
?:doi	<https://research.tib.eu/covid-19/entity/10.1080/13696998.2022.2030148>
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article>
?:journal	Journal of medical economics
is ?:pmid of	<https://research.tib.eu/covid-19/entity/35037816>
?:pmid	<https://research.tib.eu/covid-19/entity/35037816>
?:pmid	35037816
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	1.112
?:rankingScore_hIndex	33
?:title	Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/35037816>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/35037816>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all